Potential for False Negative Results Found In Prognostic Testing For Breast Cancer

the ONA take:

A recent study evaluating HER2 testing found important limitations in the conventional methods for HER2 testing. Dartmouth-Hitchcock Norris Cotton Cancer Center physicians and researchers retested tumor samples and found that some results incorrectly classified tumor types. In this study, approximately 4% of cases that were originally determined to be negative were positive on retesting. HER2 is determined via two complementary tests (immunohistochemistry [IHC] and florescence in situ hybridization [FISH]); however, in smaller laboratories, only one of the tests may be used. The researchers point out that variance may also be related to how the tests are conducted in smaller vs larger pathology laboratories.

Potential for False Negative Results Found In Prognostic Testing For Breast Cancer
Potential for False Negative Results Found In Prognostic Testing For Breast Cancer
A recent study evaluating HER2 testing in a large cohort of women with breast cancer found important limitations in the conventional way HER2 testing is performed in the US and internationally. Dartmouth-Hitchcock Norris Cotton Cancer Center physicians and researchers retested tumor samples from a large group of women and found that 22 out of 530 women had their tumor type incorrectly classified.
READ FULL ARTICLE From Science 2.0
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs